Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
58 巻, 2 号
選択された号の論文の29件中1~29を表示しています
ORIGINAL ARTICLES
  • Takashi Ichida, Syunsuke Ueyama, Tetsuya Eto, Fumihiko Kusano, Yoshino ...
    2019 年 58 巻 2 号 p. 159-166
    発行日: 2019/01/15
    公開日: 2019/01/15
    [早期公開] 公開日: 2018/09/12
    ジャーナル オープンアクセス

    Objective Gastric endoscopic submucosal dissection (ESD) is currently a standard procedure, and proton pump inhibitors (PPIs) are most commonly used to treat post-ESD ulcers. Vonoprazan, a potassium-competitive acid blocker (P-CAB), reportedly inhibits gastric acid secretions more effectively than PPIs. Combination therapy of a PPI plus rebamipide is effective for treating larger ulcers. Our goal was to evaluate the effects of vonoprazan plus rebamipide compared to esomeprazole plus rebamipide for the treatment of post-ESD ulcers.

    Methods First, vonoprazan plus rebamipide (V group) or esomeprazole plus rebamipide (E group) was orally administered to subjects for eight weeks. We then evaluated the ulcer healing process at four and eight weeks after the procedure using a gastric ulcer stage system and by measuring the ulcer size.

    Patients A total of 84 patients who underwent ESD for gastric neoplasms between September 2015 and December 2017 in Tsuchiura Kyodo General Hospital were included in this randomized controlled trial.

    Results The ulcer scar rates at week 4 in the V group (n=43) and E groups (n=39) were 20.9% and 15.4%, while those at week 8 were 90.7% and 92.3%, respectively. The ulcer reduction rates at week 4 in the V and E groups were 94.6% and 93.8%, and those at week 8 were 99.7% and 99.3%, respectively. The ulcer scar rates and reduction rates were not significantly different between the two groups.

    Conclusion Combination therapy consisting of vonoprazan plus rebamipide was not superior to that of esomeprazole plus rebamipide for post-ESD ulcer healing (UMIN000019516).

  • Maiko Takai, Takatoshi Anno, Fumiko Kawasaki, Tomohiko Kimura, Hidenor ...
    2019 年 58 巻 2 号 p. 167-173
    発行日: 2019/01/15
    公開日: 2019/01/15
    [早期公開] 公開日: 2018/08/24
    ジャーナル オープンアクセス
    電子付録

    Objective It is important to preserve the pancreatic β-cell function in order to maintain good glycemic control for a long period. The aim of this study was to examine which factors are associated with the β-cell function in subjects with type 2 diabetes mellitus.

    Methods A total of 372 subjects with type 2 diabetes who had been hospitalized for the amelioration of their glycemic control and/or education about diabetes in Kawasaki Medical School Hospital were included in this study. We evaluated the remnant β-cell function as the HOMA-%β using the computer software program HOMA2 and estimated the glycemic fluctuation with the glycoalbumin (GA)/hemoglobin A1c (HbA1c) ratio. In addition, we divided the subjects into a relatively young group (<65 years old) (n=210) and an elderly group (≥65 years old) (n=162) and performed several analyses in each group.

    Results The GA/HbA1c ratio, GA and HbA1c were independent determinant factors for the HOMA-%β regardless of age. We obtained almost the same results even after excluding those subjects using insulin secretagogues. These data suggest that the glycemic fluctuation and glycemic control are associated with the remnant β-cell function in Japanese subjects with type 2 diabetes.

    Conclusion It is very important to reduce glycemic fluctuation as well as to maintain good glycemic control in order to preserve β-cell function in subjects with type 2 diabetes.

  • Takayuki Toyama, Tomotaka Kawayama, Takashi Kinoshita, Yohei Imamura, ...
    2019 年 58 巻 2 号 p. 175-185
    発行日: 2019/01/15
    公開日: 2019/01/15
    [早期公開] 公開日: 2018/09/12
    ジャーナル オープンアクセス
    電子付録

    Objective This multicenter, cross-sectional, non-interventional trial aimed to investigate adherence barriers to inhaled medicines when compared with oral medicines in Japanese patients with chronic obstructive pulmonary disease (COPD) and asthma.

    Methods The self-reporting "Adherence Starts with Knowledge 20" (ASK-20) questionnaire was administered for adherence barriers of inhaled and oral medicines to outpatients with regular clinic attendance.

    Results Patients with COPD and asthma reported different adherence barriers to inhaled medicines. Independent adherence barriers [odds ratio (95% confidence interval)] to inhaled medicines relative to those for oral medicines among patients with COPD and asthma were those related to item Q8 [ "I know if I am reaching my health goals"; 2.49 (1.39-4.47); p=0.0022] and item Q2 [ "I run out of my medicine because I do not get refills on time"; 2.69 (1.26-5.75); p=0.0127], respectively. Among patients with poor adherence to only inhaled medicines, those with COPD and asthma recognized item Q3 [ "consuming alcohol and taking medicines"; 6.63 (1.27-34.7); p<0.05] and item Q1 [ "forget to take medicines only sometimes"; 4.29 (1.83-10.0); p<0.05], respectively, were recognized as independent adherence barriers to inhaled medicines. The total ASK-20 scores and total barrier counts in patients with poor adherence to inhaled medicines were significantly higher than in those without poor adherence among patients with asthma (p=0.0057) but not those with COPD (p>0.05).

    Conclusion These results will aid in personalizing education on adherence to inhaled medicines among patients with COPD and asthma.

  • Yusuke Hirota, Shingo Suzuki, Yoshiyuki Ohira, Kiyoshi Shikino, Masato ...
    2019 年 58 巻 2 号 p. 187-193
    発行日: 2019/01/15
    公開日: 2019/01/15
    [早期公開] 公開日: 2018/09/12
    ジャーナル オープンアクセス
    電子付録

    Objective To determine whether or not displaying the cost of tests can help reduce charges on test ordering in Japan.

    Methods This study was conducted under the setting of a simulated first visit of an outpatient for general internal medicine in a secondary medical institution in Japan. We randomly assigned 27 residents and clinical fellows to Team A or B. The first half, without charges displayed on the ordering system, was designated the "non-display group," and the participants of Team A selected tests for each paper-based simulated case (Q1-Q14), while the participants of Team B selected tests for Q15-Q28. The second half, which had charges displayed, was designated the "display group," and the participants of Team A selected tests for Q15-Q28, while the participants of Team B selected tests for Q1-Q14. The main outcome measure was the difference in the cost of tests per paper-based simulated case between the non-display and display groups.

    Results The median (interquartile range) cost of tests per paper-based simulated case was 12,255 yen (5,040-23,695 yen) in the non-display group versus 9,425 yen (2,320-21,700 yen) in the display group, showing a decrease of 2,830 yen with charges being displayed (p=0.002).

    Conclusion Displaying the charges when ordering tests in paper-based simulated cases resulted in cost reduction. The adoption of this intervention may reduce health insurance costs under the health insurance system in Japan, which has features such as universal health coverage and universal access to care.

CASE REPORTS
PICTURES IN CLINICAL MEDICINES
LETTERS TO THE EDITOR
feedback
Top